Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Prostate cancer cells and exosomes in acidic condition show increased carbonic anhydrase IX expression and activity.

Tytuł:
Prostate cancer cells and exosomes in acidic condition show increased carbonic anhydrase IX expression and activity.
Autorzy:
Logozzi M; a Department of Oncology and Molecular Medicine , National Institute of Health , Rome , Italy.
Capasso C; b National Research Council , Institute of Biosciences and BioResources , Naples , Italy.
Di Raimo R; a Department of Oncology and Molecular Medicine , National Institute of Health , Rome , Italy.
Del Prete S; b National Research Council , Institute of Biosciences and BioResources , Naples , Italy.
Mizzoni D; a Department of Oncology and Molecular Medicine , National Institute of Health , Rome , Italy.
Falchi M; c National AIDS Center , National Institute of Health , Rome , Italy.
Supuran CT; d NEUROFARBA Department , University of Florence, Section of Pharmaceutical Chemistry , Florence , Italy.
Fais S; a Department of Oncology and Molecular Medicine , National Institute of Health , Rome , Italy.
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2019 Dec; Vol. 34 (1), pp. 272-278.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basingstoke, UK : Taylor & Francis, c2002-
MeSH Terms:
Antigens, Neoplasm/*metabolism
Carbonic Anhydrase IX/*metabolism
Exosomes/*metabolism
Prostatic Neoplasms/*metabolism
Antigens, Neoplasm/biosynthesis ; Carbonic Anhydrase IX/biosynthesis ; Cell Line, Tumor ; Exosomes/pathology ; Humans ; Hydrogen-Ion Concentration ; Male ; Microscopy, Confocal ; Prostatic Neoplasms/pathology
References:
Bioorg Med Chem. 1999 Nov;7(11):2397-406. (PMID: 10632049)
Novartis Found Symp. 2001;240:251-60; discussion 260-4. (PMID: 11727934)
Clin Cancer Res. 2002 Apr;8(4):1284-91. (PMID: 11948144)
Nat Rev Immunol. 2002 Aug;2(8):569-79. (PMID: 12154376)
J Magn Reson Imaging. 2002 Oct;16(4):430-50. (PMID: 12353258)
Virology. 1992 Apr;187(2):620-6. (PMID: 1312272)
Science. 1956 Feb 24;123(3191):309-14. (PMID: 13298683)
Aliment Pharmacol Ther. 2003 Oct 15;18(8):837-46. (PMID: 14535878)
Cancer Treat Rev. 2003 Dec;29(6):541-9. (PMID: 14585264)
Nat Rev Cancer. 2004 Nov;4(11):891-9. (PMID: 15516961)
J Natl Cancer Inst. 2004 Nov 17;96(22):1702-13. (PMID: 15547183)
FEBS Lett. 2004 Nov 19;577(3):439-45. (PMID: 15556624)
Bioorg Med Chem Lett. 2005 Jun 15;15(12):3102-8. (PMID: 15905091)
J Med Chem. 2005 Sep 8;48(18):5721-7. (PMID: 16134940)
J Enzyme Inhib Med Chem. 2005 Aug;20(4):333-40. (PMID: 16206827)
Cancer Res. 2006 Apr 1;66(7):3629-38. (PMID: 16585188)
Cancer Res. 2007 Jun 1;67(11):5408-17. (PMID: 17545622)
J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54. (PMID: 17895480)
Cancer Res. 2007 Nov 15;67(22):10627-30. (PMID: 18006801)
BJU Int. 2008 Jun;101 Suppl 4:8-15. (PMID: 18430116)
Biochim Biophys Acta. 2009 Apr;1795(2):162-72. (PMID: 19344680)
PLoS One. 2009;4(4):e5219. (PMID: 19381331)
Science. 2009 May 22;324(5930):1029-33. (PMID: 19460998)
Biochem Biophys Res Commun. 2009 Aug 28;386(3):488-92. (PMID: 19538935)
J Biol Chem. 2009 Dec 4;284(49):34211-22. (PMID: 19801663)
Int J Cancer. 2010 Jul 1;127(1):207-19. (PMID: 19876915)
J Biol Chem. 2010 Jun 4;285(23):17442-52. (PMID: 20353945)
J Pharmacol Exp Ther. 2010 Sep 1;334(3):710-9. (PMID: 20519553)
Neurochem Res. 2011 Sep;36(9):1594-600. (PMID: 21136156)
Nat Rev Cancer. 2011 Feb;11(2):85-95. (PMID: 21258394)
Chem Biol Drug Des. 2011 Jun;77(6):494-9. (PMID: 21332948)
J Med Chem. 2011 Mar 24;54(6):1896-902. (PMID: 21361354)
Cell Death Dis. 2010 Oct 21;1:e87. (PMID: 21368860)
Cancer Res. 2011 May 1;71(9):3364-76. (PMID: 21415165)
Radiother Oncol. 2011 Jun;99(3):424-31. (PMID: 21676479)
Nat Rev Drug Discov. 2011 Sep 16;10(10):767-77. (PMID: 21921921)
Cancer Res. 2012 Jun 1;72(11):2746-56. (PMID: 22593198)
Chem Rev. 2012 Aug 8;112(8):4421-68. (PMID: 22607219)
Expert Opin Ther Pat. 2013;23(6):737-49. (PMID: 23672415)
Front Physiol. 2013 Oct 01;4:271. (PMID: 24101905)
Mol Carcinog. 2015 Jul;54(7):554-65. (PMID: 24347249)
Philos Trans R Soc Lond B Biol Sci. 2014 Feb 03;369(1638):20130100. (PMID: 24493748)
PLoS One. 2014 Feb 06;9(2):e88193. (PMID: 24516610)
Angew Chem Int Ed Engl. 2014 Apr 14;53(16):4231-5. (PMID: 24623670)
Front Physiol. 2014 Apr 16;5:130. (PMID: 24795638)
Leuk Lymphoma. 2015 May;56(5):1432-9. (PMID: 25130478)
Cancer Metastasis Rev. 2014 Dec;33(4):1095-108. (PMID: 25376898)
Cancer Lett. 2015 Jan 28;356(2 Pt B):697-703. (PMID: 25449440)
Biochim Biophys Acta. 2015 Feb;1847(2):171-181. (PMID: 25449966)
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2715-26. (PMID: 25449995)
Oncol Res Treat. 2015;38(3):117-22. (PMID: 25792083)
J Extracell Vesicles. 2015 May 14;4:27066. (PMID: 25979354)
J Enzyme Inhib Med Chem. 2016 Aug;31(4):538-45. (PMID: 26018420)
J Enzyme Inhib Med Chem. 2016 Oct;31(5):689-94. (PMID: 26118417)
J Enzyme Inhib Med Chem. 2016;31(3):345-60. (PMID: 26619898)
ACS Nano. 2016 Apr 26;10(4):3886-99. (PMID: 26978483)
Cancer Lett. 2016 Jul 1;376(2):278-83. (PMID: 27084522)
J Enzyme Inhib Med Chem. 2016;31(sup1):119-125. (PMID: 27142956)
Diagn Pathol. 2016 May 25;11(1):45. (PMID: 27225200)
Biochem J. 2016 Jul 15;473(14):2023-32. (PMID: 27407171)
Oncotarget. 2016 Aug 23;7(34):54676-54690. (PMID: 27419627)
PLoS One. 2016 Jul 22;11(7):e0159763. (PMID: 27447181)
Expert Opin Drug Discov. 2017 Jan;12(1):61-88. (PMID: 27783541)
Eur J Pharm Sci. 2017 Feb 15;98:64-69. (PMID: 27840195)
Semin Cancer Biol. 2017 Apr;43:111-118. (PMID: 28088584)
Cancer Lett. 2017 Sep 10;403:318-329. (PMID: 28694142)
J Enzyme Inhib Med Chem. 2017 Dec;32(1):908-916. (PMID: 28708430)
J Enzyme Inhib Med Chem. 2017 Dec;32(1):1002-1011. (PMID: 28738704)
Biochem Biophys Res Commun. 2017 Oct 21;492(3):356-361. (PMID: 28851650)
Cancer Chemother Pharmacol. 2017 Nov;80(5):925-937. (PMID: 28861639)
Nat Rev Cancer. 2017 Oct;17(10):577-593. (PMID: 28912578)
Metabolites. 2017 Sep 16;7(3):null. (PMID: 28926956)
J Mol Med (Berl). 2017 Dec;95(12):1341-1353. (PMID: 28929255)
Biochim Biophys Acta Rev Cancer. 2018 Jan;1869(1):64-77. (PMID: 29175553)
JCI Insight. 2017 Dec 21;2(24):null. (PMID: 29263302)
Metabolites. 2017 Dec 23;8(1):null. (PMID: 29295495)
Bioorg Chem. 2018 Apr;77:381-386. (PMID: 29421714)
Metabolites. 2018 Mar 08;8(1):null. (PMID: 29517989)
Metabolites. 2018 Mar 21;8(2):null. (PMID: 29561812)
J Enzyme Inhib Med Chem. 2018 Dec;33(1):804-808. (PMID: 29706097)
Drug Resist Updat. 2018 May;38:1-11. (PMID: 29857814)
Oncoimmunology. 2018 Mar 26;7(7):e1445452. (PMID: 29900055)
J Med Chem. 2018 Jul 26;61(14):6328-6338. (PMID: 29962205)
Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1127-31. (PMID: 8430084)
J Pharm Sci. 1994 Jun;83(6):768-73. (PMID: 9120804)
Br J Cancer. 1998 Jun;77(11):1726-31. (PMID: 9667639)
Contributed Indexing:
Keywords: LNCaP; Tumour microenvironment; cancer; carbonic anhydrase IX; exosomes
Substance Nomenclature:
0 (Antigens, Neoplasm)
EC 4.2.1.1 (CA9 protein, human)
EC 4.2.1.1 (Carbonic Anhydrase IX)
Entry Date(s):
Date Created: 20190209 Date Completed: 20190314 Latest Revision: 20200225
Update Code:
20240105
PubMed Central ID:
PMC6327996
DOI:
10.1080/14756366.2018.1538980
PMID:
30734594
Czasopismo naukowe
Acidity and hypoxia are crucial phenotypes of tumour microenvironment both contributing to the selection of malignant cells under a micro evolutionistic pressure. During the tumour progression, nanovesicles, called exosomes and the metalloenzyme carbonic anhydrase IX (CA IX) affect the tumour growth and proliferation. Exosomes are released into the tumour microenvironment and spilt all over the body, while CA IX is a tumour-associated protein overexpressed in many different solid tumours. In the present study, to better understand the relationships between exosomes and CA IX, it has been used an in vitro cellular model of cells cultured in different pH conditions. The results showed that the acidic microenvironment induced upregulation of both expression and activity of CA IX in cancer cells and their exosomes, together with increasing the number of released exosomes. These data strongly support the importance of CA IX as a cancer biomarker and as a valuable target of new anticancer therapies.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies